Chart-Typ:
Zeitraum:
| XFRA PBN0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
| XFRA PBN0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILALTERITY THERAP.ADR/600... ► Artikel lesen |
| XFRA NEW INSTRUMENTS AVAILABLE ON 20.08.2025 | The following instruments on XETRA do have their first trading 20.08.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.08.2025
Aktien
1 US02155X2053 Alterity Therapeutics... ► Artikel lesen |
| SurgePays, Inc.: SurgePays Unveils ProgramBenefits.com as Next Phase in Data Monetization Strategy | New platform converts an established lead-generation system into a scalable intake and data monetization engine targeting the underserved and subprime consumer market. Proven legacy software reengineered... ► Artikel lesen |
| SurgePays, Inc.: SurgePays Revenue for the Third Quarter 2025 Increases 292% Year-Over-Year and 62% Sequentially | Third quarter 2025 revenue totaled approximately $18.7 million, an increase of 292% year-over-year and 62% sequentially Company is reiterating revenue guidance for 2026 of $225 million Conference... ► Artikel lesen |
| SurgePays, Inc.: SurgePays Signs Strategic Agreement with Payment Technology Provider, QorPay, to Integrate ClearLine into Next-Generation Payments Solution and Accelerate New Growth Channel | BARTLETT, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- SurgePays, Inc. (NASDAQ: SURG) ("SurgePays" or the "Company"), a wireless and point-of-sale technology company, today announced a new strategic partnership... ► Artikel lesen |
| Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC | TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8Clinically Meaningful Reductions in Arrhythmia Burden... ► Artikel lesen |
| Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy | SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially... ► Artikel lesen |
| Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025 | Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK-1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy Second Late-Breaking... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LINKHOME HOLDINGS INC finden Sie auf Wallstreet Online.